The knockdown of VIM in late stage cancer serum-derived exosomes demonstrated that the migratory ability of HBECs treated by the VIM depleted exosomes was reduced, and the VIM expression in the treated HBECs was also decreased. This evidence concerns the gene VIM and cancer.